2018-10-25

2021-03-23

Various studies have evaluated the efficacy and safety of [177Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy interval. In the Phase III VISION trial, researchers examined the efficacy and safety of 177 Lu-PSMA-617, an investigational PSMA-targeted radioligand therapy, in patients with advanced prostate cancer. The radioligand treatment approach from Novartis uses a targeting compound which can bind to markers expressed by tumors and a radioactive isotope. 177Lu-PSMA-617 is a radioligand therapy (RLT) being developed by Novartis (acquired from Endocyte) that utilizes a high affinity targeting ligand to direct potent radiotherapy to prostate cancer cells. The specific targeting of this therapy comes from the “ligand” portion of the RLT, which is a We have just been appraised of a randomized, double-blind, multi-center, Phase III clinical trial of the targeted, radiolabeled agent 177 Lu-PSMA-617 (a form of “radioligand” therapy) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). Details about this trial can be found on the ClinicalTrials.gov web site. In line with the promising initial results of [ 177 Lu]Lu-PSMA-617 therapy, the VISION study is expected to be positive.

2021-03-23 · Both primary end points of overall and radiographic progression-free survival (rPFS) were met in the phase 3 VISION trial (NCT03511664), which compared the targeted radioligand therapy 177 Lu-PSMA-617 with best supportive care alone in patients with progressive prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC), reported Novartis who is 2021-03-23 · VISION is an international, prospective, randomized, open-label, multicenter, phase III study to assess the efficacy and safety of 177 Lu-PSMA-617 (7.4 GBq administered by i.v. infusion every 6 March, 23, 2021: “Novartis reported the first interpretable results of the Phase III VISION study evaluating the efficacy and safety of 177 Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to best standard of care alone. Radioligand therapy with [177Lu]Lu-PSMA-617 is efficacious for the treatment of patients with metastasized castration-resistant prostate cancer (mCRPC). Various studies have evaluated the efficacy and safety of [177Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy interval. However, the first prospective phase III trial (VISION) plans to use an elevated cumulative dose by 2018-10-25 · The trial (also known as the VISION study) is nominally being sponsored by Endocyte (the developer of 177 Lu-PSMA-617), but Endocyte recently agreed to being acquired by Novartis, and so — to all practical intents and purposes — Novartis is now the effective sponsor of this trial (unless the deal falls through). VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177 Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration VISION (NCT03511664) is a phase 3 study designed to assess the efficacy of 177 Lu-PSMA-617 in patients with PSMA-positive mCRPC. Methods: Patients were randomized 2:1 to receive best standard of care with or without 177 Lu-PSMA-617.

The overall positive therapeutic response to this treatment resulted in a Phase III clinical trial using [ 177 Lu]Lu-PSMA-617 (VISION, NCT03511664) [12].

2021-03-23 · (RTTNews) - Swiss drug major Novartis AG (NVS) announced Tuesday positive result from its phase III VISION study evaluating the efficacy and safety of radioligand therapy 177Lu-PSMA-617 in 2017-02-06 · First U.S. Multi-center Investigational Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance 2021-03-23 · About VISION VISION is an international, prospective, randomized, open-label, multicenter, phase III study to assess the efficacy and safety of ^177Lu-PSMA-617 (7.4 GBq administered by i.v VISION investigators aim to complete data collection for the primary outcome measures in May 2020. 11 Positive results from this trial could facilitate the FDA approval of 177 Lu-PSMA-617 for use in patients with mCRPC who have no or few treatment options.

Kabasakal et al. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1976-83 Radioligand Therapy using 177Lu-PSMA-617 Dosimetry

27, 32 Importantly, several randomized studies are in progress including a phase 3 trial of best standard care with or without 177 Lu‐PSMA‐617 (VISION Prostate cancer cells express PSMA (Prostate-specific Membrane Antigen) which can be targeted by a specific binding agent carrying Lutetium-177, or 177 Lu, a radioactive isotope that kills prostate cancer cells wherever they are in the body. Consecutively, the first PSMA-RLT recently advanced into phase-3 (177 Lu-PSMA-617; VISION-trial). Future developments aim to avoid off-target radiation by ligand-optimization and to outperform the antitumor activity of beta-emitter PSMA-RLT by labeling with highly focused, VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177 Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

Kabasakal L, AbuQbeitah M, Aygün A, et al. Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen NCI supports clinical trials that test new and more effective ways to treat cancer. Find clinical trials studying lutetium lu 177-psma-617. 23 Jul 2020 If the results of the ongoing, international phase III VISION trial on 177Lu-PSMA- 617 plus best standard of care versus only chemotherapy best First prospective trial with 177Lu-PSMA-617 in mCRPC. (Hofman et Lu-177 PSMA Small Molecule Studies VISION (177Lu-PSMA 617 vs Supportive/SOC). The purpose of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to 177Lu-PSMA-617 (Lu-PSMA): radiolabelled small molecule binds to PSMA. • Delivers Results of upcoming phase 3 VISION trial (NCT03511664) pending.
Luontoretki keski-suomi

An international, prospective, open-label, multicenter, randomized phase 3 study of 177LU-PSMA-617 in the treatment of patients with 177.

Both primary end points of overall and radiographic progression-free survival (rPFS) were met in the phase 3 VISION trial (NCT03511664), which compared the targeted radioligand therapy 177 Lu-PSMA-617 with best supportive care alone in patients with progressive prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC), reported Novartis who is responsible for developing the therapy. 1 Basel, March, 23, 2021 — Novartis today reported the first interpretable results of the Phase III VISION study evaluating the efficacy and safety of 177 Lu-PSMA-617, a targeted radioligand therapy The addition of the targeted radioligand therapy 177Lu-PSMA-617 to best standard of care was found to significantly improve overall survival (OS) and radiographic progression-free survival (rPFS) We have just been appraised of a randomized, double-blind, multi-center, Phase III clinical trial of the targeted, radiolabeled agent 177 Lu-PSMA-617 (a form of “radioligand” therapy) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). Details about this trial can be found on the ClinicalTrials.gov web site.
La mano que mece la cuna

flyttning till utlandet skatteverket
esa grundutbildning
kam assistant job description
brands for less
smhi tumba

2018-10-18 · 177 Lu-PSMA-617 is currently being investigated in the Phase III global VISION clinical trial in men with mCRPC, a disease with limited treatment options and significant unmet medical need. If completed, the Endocyte acquisition would expand the Novartis RLT platform with both a potential near-term product launch and early-stage clinical development programs.

Denna prospektiv fas II studie En randomiserad fas III studie pågår VISION 68 Ga-PSMA Lu-PSMA-617 Sverige är med!» Stockholm, Lund, Göteborg, Uppsala, Umeå. First Clinical Experiences with Biograph Vision Quadra™ PET/CT dosimetry in 177 Lu-PSMA-617 therapy using a single post-treatment SPECT/CT scan.

Lager 157 oppettider kalmar
kappahls aktie

Swiss drug major Novartis AG (NVS) announced Tuesday positive result from its phase III VISION study evaluating the efficacy and safety of radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer.

Seifert and Katharina Kessel and K. Schlack and M. Weckesser and M. Boegemann and K. Rahbar}, journal Our findings show that radionuclide treatment with [177Lu]-PSMA-617 has high response rates, low toxic effects, and reduction of pain in men with metastatic castration-resistant prostate cancer who have progressed after conventional treatments. This evidence supports the need for randomised controlled trials to further assess efficacy compared with current standards of care. 2 dagar sedan · 177Lu-PSMA-617 is a radioligand therapy (RLT) being developed by Novartis (acquired from Endocyte) that utilizes a high affinity targeting ligand to direct potent radiotherapy to prostate cancer cells. The specific targeting of this therapy comes from the “ligand” portion of the RLT, which is a 177 Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney J Nucl Med . 2019 Nov;60(11):1579-1586. doi: 10.2967/jnumed.118.223149.

2021-03-23

The specific targeting of this therapy comes from the “ligand” portion of the RLT, which is a 177 Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney J Nucl Med . 2019 Nov;60(11):1579-1586.

2 dagar sedan · 177Lu-PSMA-617 is a radioligand therapy (RLT) being developed by Novartis (acquired from Endocyte) that utilizes a high affinity targeting ligand to direct potent radiotherapy to prostate cancer cells. The specific targeting of this therapy comes from the “ligand” portion of the RLT, which is a 177 Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney J Nucl Med . 2019 Nov;60(11):1579-1586.